Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas (2021)
Fonte: Molecules. Unidade: ICB
Assuntos: FARMACOLOGIA, APOPTOSE, PRODUTOS NATURAIS, PEPTÍDEOS, AMINOÁCIDOS, CÉLULAS CULTIVADAS DE TUMOR, MELANOMA, MOLÉCULA, BACTÉRIAS AERÓBICAS
ABNT
HIRATA, Amanda Soares et al. Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas. Molecules, v. 26, n. 23, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.3390/molecules26237362. Acesso em: 09 out. 2024.APA
Hirata, A. S., Teixeira, P. R., Machado Neto, J. A., Jimenez, P. C., Clair, J. J. L., Fenical, W., & Costa-Lotufo, L. V. (2021). Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas. Molecules, 26( 23), 1-15. doi:10.3390/molecules26237362NLM
Hirata AS, Teixeira PR, Machado Neto JA, Jimenez PC, Clair JJL, Fenical W, Costa-Lotufo LV. Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas [Internet]. Molecules. 2021 ; 26( 23): 1-15.[citado 2024 out. 09 ] Available from: https://doi.org/10.3390/molecules26237362Vancouver
Hirata AS, Teixeira PR, Machado Neto JA, Jimenez PC, Clair JJL, Fenical W, Costa-Lotufo LV. Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas [Internet]. Molecules. 2021 ; 26( 23): 1-15.[citado 2024 out. 09 ] Available from: https://doi.org/10.3390/molecules26237362